Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-05-17
2011-05-17
Huff, Sheela J (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07943577
ABSTRACT:
Therapeutic compounds which are cell proliferation modulators, preferably inhibitors. These modulators contain amino acid structures that are arranged as a hydrophilic analog of an alpha-fetoprotein. The modulator may be a peptide itself, e.g., an octapeptide like that of SEQ ID NO: 5; a peptidomimetic; or may be in the form of a pharmaceutically acceptable scaffold, such as a polycyclic hydrocarbon to which is attached the necessary amino acid structures for biological and/or chemical activity. The modulators of the invention are distinguished in one aspect over previous compounds in that they are orally active, and therefore do not have to be injected into the patient. The compositions and methods are useful for reducing estrogen-dependent and estrogen-independent growth of cells, and treating or preventing cancer, such as breast cancer, brain cancer, head-and-neck cancer, thyroid cancer, lung cancer, colon cancer, ovarian cancer, prostate cancer, cervical cancer, and skin cancer. The treatment or prevention methods can include the use of tamoxifen therapy in combination with the peptide therapy.
REFERENCES:
patent: 5674842 (1997-10-01), Mizejewski
patent: 5707963 (1998-01-01), Mizejewski
patent: 6306832 (2001-10-01), Pietras
patent: 6818741 (2004-11-01), Andersen et al.
patent: 7122522 (2006-10-01), Andersen et al.
patent: 7238340 (2007-07-01), McBride et al.
patent: 1401467 (2004-03-01), None
patent: WO-9613581 (1996-05-01), None
patent: WO-03007978 (2003-01-01), None
Allen et al., “Purification of Alpha-Fetoprotein from Human Cord Serum with Demonstration of its Antiestrogenic Activity”, Biochimica et Biophysica Acta,1202:135-142 (1993).
Atanaskova et al., “Map kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance”, Oncogene, 21(25):4000-4008 (2002).
Bedo et al., “Retinoic Acid Regulates Growth Hormone Gene Expression”, Nature, 339:231-234 (1989).
Bennett et al., “A Peptide Derived from α-Fetoprotein Prevents the Growth of Estrogen-Dependent Human Breast Cancers Sensitive and Resistant to Tamoxifen”, Proc. Natl. Acad. Sci. U.S.A., 99(4):2211-2215 (2002).
Bennett et al., “An α-Fetoprotein-Derived Peptide Inhibits Estrogen Receptor Positive Breast Cancers, Sensitive and Resistant to Tamoxifen”, Proc. Am. Assoc. Can. Res., 42:238 (2001) (Abstract Only).
Bennett et al., “Transformation of Alpha-Fetoprotein (AFP) to a Negative Regulator of Estrogen-Dependent Growth by Ligands of the Steroid/Thyroid Hormone Receptor Superfamily”, Proc. Am. Assoc. Can. Res., 34:244 (1993) (Abstract Only).
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue”, J. Cell Biol., 111:2129-2138 (1990).
Collins et al., “Spontaneous Cessation of Friend Murine Leukemia Virus Production by Leukemia Cell Line Y57: Overgrowth by Nonproducer Cells”, J. Natl. Cancer Inst., 64(5):1153-1159 (1980).
Conti et al., “Thyroid Hormone Effect on α-Fetoprotein and Albumin Coordinate Expression by a Human Hepatoma Cell Line”, Biochimica et Biophysica Acta, 1008:315-321 (1989).
Dauphinee et al., “Peptide Suppression of Breast Cancer Growth: In Search of Mechanisms by Identification of Cellular Targets”, Breast Cancer Res. Treat., 64:109 (2000) (Abstract Only).
Dietrich, W., “New Aspects of Steroid Hormone Dependent Tumor Growth”,Arch. Geschwulstforsch., 60:149-160 (1990).
Duan et al., “Estrogen Receptor-mediated Activation of the Serum Response Element in MCF-7 Cells Through MAPK-dependent Phosphorylation of Elk-1”,J. Biol. Chem., 276(15):11590-11598 (2001).
Eisele et al., “Studies on a Growth-Inhibitory Peptide Derived from Alpha-Fetoprotein and Some Analogs”,J. Pept. Res., 57:29-38 (2001).
Eisele et al., “Studies on Analogs of a Peptide Derived from Alpha-Fetoprotein Having Antigrowth Properties”,J. Pept. Res., 57:539-546 (2001).
Evans, R.M., “The Steroid and Thyroid Hormone Receptor Superfamily”,Science, 240:889-895 (1988).
Garreau et al., “Phytoestrogens: New Ligands for Rat and Human α-Fetoprotein”,Biochimica et Biophysica Acta, 1094:339-345 (1991).
Gekonge et al., “Regulation of Estrogen Activity by an Antiestrotrophic α-Fetoprotein Peptide”,Proc. Am. Assoc. Can. Res., 42: 239 (2001) (Abstract Only).
Gura, T., “Systems for Identifying New Drugs Are Often Faulty”,Science, 278:1041-1042 (1997).
International Search Report for PCT/US02/37070, mailed on Jul. 10, 2003.
International Search Report for PCT/US02/37291, mailed on Aug. 29, 2003.
Jacobson et al., “Anti Breast-Cancer Peptides Derived from Alpha-Fetoprotein”, Abstract published in Cancer Detection and Prevention 2000; 24 (Supplement 1); <http://www.cancerprev.org/Journal/Issues/24/101/409/3220> (2000).
Jacobson et al., “Estradiol-Induced Changes in Spectral and Biological Properties of Alpha-Fetoprotein”,Tumor Biol., 11:104 (1990).
Jacobson et al., “Inhibition of Estrogen-Dependent Breast Cancer Growth by a Reaction Product of α-Fetoprotein and Estradiol”,Cancer Res., 50:415-420 (1990).
Jacobson et al., “Pregnancy-Altered Breast Cancer Risk: Mediated by Maternal Serum AFP?”, inBiological Activities of Alpha1-Fetoprotein, Chapter 8, vol. II, pp. 93-100 (1989).
Keel et al., “Purified Human α-Fetoprotein Inhibits Follicle-Stimulating Hormone-Stimulated Estradiol Production by Porcine Granulosa Cells in Culture”,Mol. Cell. Endocrinol., 94:21-25 (1993).
Keel et al., “Purified Human Alpha-Fetoprotein Inhibits Growth Factor-Stimulated Estradiol Production by Porcine Granulosa Cells in Monolayer Culture”,Endocrinol., 130(6):3715-3717 (1992).
Kini et al., “A common structural feature enclosing interaction sites: Prediction of protein-protein interaction sites and development of potent bioactive peptides”,Curr. Topics Pep. Prot. Res., 1:297-311 (1994).
Larner et al., “Binding of Estradiol-17-Fatty Acid Esters to Plasma Proteins”,Endocrinol., 121(2):738-744 (1987).
Lazar et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities”,Mol. Cell. Biol., 8(3):1247-1252 (1988).
Li et al., “AFP-L3: A New Generation of Tumor Marker for Hepatocellular Carcinoma”,Clinica Chimica Acta, 313:15-19 (2001).
MacColl et al., “Interrelationships Among Biological Activity, Disulfide Bonds, Secondary Structure, and Metal Ion Binding for a Chemically Synthesized 34-Amino-Acid Peptide Derived from α-Fetoprotein”,Biochimica et Biophysica Acta, 1528:127-134 (2001).
Mesfin et al., “Alpha-Fetoprotein-Derived Antiestrotrophic Octapeptide”,Biochimica et Biophysica Acta, 1501:33-43 (2000).
Mesfin et al., “Development of a Synthetic Cyclized Peptide Derived from α-Fetoproteinthat Prevents the Growth of Human Breast Cancer”, J. Pept. Res., 58:246-256 (2001).
Mesfin et al., “Anti-Estrotrophic and Anti-Breast Cancer Activity of an AFP-Derived Octapeptide”,Proc. Am. Assoc. Can Res., 41:375 (2000) (Abstract Only).
Mesfin et al., “Novel Analogs in an Anti-Breast Cancer Octapeptide”,Proc. Am. Assoc. Can. Res., 42:778-779 (2001) (Abstract Only).
Mizejewski, G. J., “An Apparent Dimerization Motif in the Third Domain of Alpha-Fetoprotein: Molecular Mimicry of the Steroid/Thyroid Nuclear Receptor Superfamily”,BioEssays, 15(5):427-432 (1993).
Mizejewski, G.J., “New Insights into AFP Structure and Function: Potential Biomedical Applications”, inAlpha-Fetoprotein and Congenital Disorders, G.J. Mizejewski and I.H. Porter, Eds., Academic Press, Inc.,
Andersen Thomas T.
Bennett James A.
Jacobson Herbert I.
Mesfin Fassil B.
Albany Medical College
Huff Sheela J
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Alpha-fetoprotein peptides and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha-fetoprotein peptides and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha-fetoprotein peptides and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2669262